Publication Name	World Journal of Gastrointestinal Pharmacology and Therapeutics
Manuscript ID	97381
Country	Egypt

Received	2024-05-29 22:06
Peer-Review Started	2024-05-29 22:06
To Make the First Decision
Return for Revision	2024-08-15 19:46
Revised	2024-08-28 07:35
Second Decision	2024-09-23 02:40
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-09-23 10:43
Articles in Press	2024-09-23 10:43
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-09-30 10:54
Publish the Manuscript Online	2024-10-25 03:02

ISSN	2150-5349 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Minireviews
Article Title	Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis
Manuscript Source	Invited Manuscript
All Author List	Mohamed Abdel-Samiee, Essam Salah Ibrahim, Mohamed Kohla, Eman Abdelsameea and Mohsen Salama
ORCID	Author(s) ORCID Number Mohamed Abdel-Samiee http://orcid.org/0000-0002-8970-0286 Mohamed Kohla http://orcid.org/0000-0001-9570-4796 Eman Abdelsameea http://orcid.org/0000-0002-3225-7164
Funding Agency and Grant Number
Corresponding Author	Eman Abdelsameea, MD, Full Professor, Department of Hepatology and Gastroenterology, National Liver Institute, Menoufia University, Shebin El-Kom 32511, Egypt. eabdelsameea@liver-eg.org
Key Words	Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Myofibroblasts; Fibrosis; Antifibrotic pharmacotherapy; Nonalcoholic fatty liver disease treatment strategies; Emerging treatments for nonalcoholic steatohepatitis
Core Tip	Non-alcoholic fatty liver disease (NAFLD) global incidence is escalating significantly. NAFLD covers a range of liver conditions, from simple steatosis to the more severe form known as non-alcoholic steatohepatitis, which involves chronic liver inflammation and the transformation of hepatic stellate cells into myofibroblasts that generate excess extracellular matrix, leading to fibrosis. Hepatocyte ballooning is a key catalyst for fibrosis progression.
Publish Date	2024-10-25 03:02
Citation	<p>Abdel-Samiee M, Ibrahim ES, Kohla M, Abdelsameea E, Salama M. Regression of hepatic fibrosis after pharmacological therapy for nonalcoholic steatohepatitis. <i>World J Gastrointest Pharmacol Ther</i> 2024; 15(6): 97381</p>
URL	https://www.wjgnet.com/2150-5349/full/v15/i6/97381.htm
DOI	https://dx.doi.org/10.4292/wjgpt.v15.i6.97381

Full Article (PDF)	WJGPT-15-97381-with-cover.pdf
Manuscript File	97381_Auto_Edited_035506.docx
Answering Reviewers	97381-answering-reviewers.pdf
Audio Core Tip	97381-audio.mp3
Conflict-of-Interest Disclosure Form	97381-conflict-of-interest-statement.pdf
Copyright License Agreement	97381-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	97381-non-native-speakers.pdf
Peer-review Report	97381-peer-reviews.pdf
Scientific Editor Work List	97381-scientific-editor-work-list.pdf
Scientific Editor Work List	97381-scientific-editor-work-list.png
CrossCheck Report	97381-crosscheck-report.pdf
CrossCheck Report	97381-crosscheck-report.png